Jeffrey S Weber

Author PubWeight™ 10.53^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.	Lancet	2014	8.63
2	Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.	Lancet Oncol	2015	2.80
3	Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.	Lancet Oncol	2017	0.75